<DOC>
	<DOCNO>NCT02054338</DOCNO>
	<brief_summary>The combination vinflunine gemcitabine advance breast cancer comparison paclitaxel gemcitabine base follow point : significant antitumour activity vinflunine metastatic breast cancer ( MBC ) single agent anthracycline-taxane exposure recent phase I study result vinflunine plus gemcitabine least additive drug distinct mechanism action ; since taxanes approve adjuvant set widely use treatment early breast cancer worthwhile assess new combination chemotherapy regimens first line therapy metastatic breast cancer .</brief_summary>
	<brief_title>A Study Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>female patient 18 year old less 75 year old histologically/cytologically confirm breast cancer document locally recurrent metastatic breast cancer HER2 negative unknown prior neo and/or adjuvant anthracyclinebased chemotherapy measurable nonmeasurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.0 adequate haematological , hepatic renal function ECG without clinically relevant abnormality know clinical evidence brain metastasis leptomeningeal involvement history second primary malignancy patient sole tumour lesion : malignant effusion , lymphangitis , cystic lesion , bone lesion , lesion assess image technique colour photography preexist motor/ensory grade &gt; 1 peripheral neuropathy prior therapy vinca alkaloid and/or gemcitabine history severe hypersensitivity vinca alkaloid and/or gemcitabine contraindication drug pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>